A CEO's primary role differs fundamentally based on company type. In an asset-centric biotech, the CEO must act as a hands-on program manager, micromanaging execution. In a platform company, the CEO must be deeply embedded in the science to predict and leverage the technology's long-term trajectory.

The rise of part-time C-suite roles in biotech offers a hidden advantage by cross-pollinating experience between startups. However, this model risks diluting the intense, "back-to-the-wall" ownership and singular mission focus that is crucial for a new company's success, creating a have/have-not divide.

Investors don't look for a specific personality type in biotech founders. Instead, they use pattern recognition to identify a crucial trait: executional excellence. The ability to expertly manage the diverse functions of a biotech company—from clinical to CMC to regulatory—is paramount, and prior experience is the best indicator of this skill.

In the early stages, a biotech CEO's role is primarily scientific leadership and storytelling to attract investors. As the company and market mature, the role shifts. Effective CEOs must then become adaptable strategists, staying true to their core vision while responding to the dynamic industry environment.

Adam Rogers became CEO of his first company, Hemera, not because he aspired to the title, but because he was the most committed person to drive the project forward. This shows how leadership can emerge organically from dedication and necessity in an early-stage venture, rather than a pre-defined career path.

The transition from a resource-rich environment like Novartis to an early-stage biotech reveals a stark contrast. The unlimited access to a global organization is replaced by a total reliance on a small, nimble team where everyone must be multi-skilled and hands-on, a change even experienced executives find jarring.

The transition from academic scientist to biotech CEO involves a critical mindset shift. In academia, ideas and knowledge are the primary capital. In the resource-intensive biotech world, time is the scarcest and most valuable asset, demanding parallel execution.

Investor preference for CEOs has shifted dramatically. While 2019-2021 favored scientific founder-CEOs, today’s tough market demands leaders with prior CEO experience. The ideal candidate has a "matrix organization" background, understanding all business functions, not just the science.

The M&A Science founder stepped back as CEO from his scaling software company, Dealroom, because his strength is in the early "boots on the ground" phase, not optimization and process maturity. This highlights the importance for founders to align their role with their core strengths rather than clinging to a title.